The trial schema is shown below.
The study aims to recruit 1100 men across 100 sites in 6 countries. The primary endpoint is metastasis-free survival, with key secondary endpoints of overall survival, prostate cancer specific survival, PSA progression free survival, time to subsequent hormonal therapy and time to castration-resistance.
Presented by: Tamim Niazi, MDCM, Jewish General Hospital, Montreal, Canada
Written by: Alok Tewari, MD, PhD, Medical Oncologist at the Dana-Farber Cancer Institute, at the 2020 European Society for Medical Oncology Virtual Congress (#ESMO20), September 19th-September 21st, 2020.
DASL-HiCAP (ANZUP1801): The Impact of Darolutamide on Standard Therapy for Localized Very High-risk Cancer of the Prostate - Christopher Sweeney
Clinical Trial Information: NCT04136353
First Patient Enrolled in Sydney in Worldwide Prostate Cancer Trial (DASL-HiCaP)
Abstract: DASL-HiCAP (ANZUP1801): The Impact of Darolutamide on Standard Therapy for Localized Very High-risk Cancer of the Prostate - Christopher Sweeney